Cancer Drug Resistance

cdr

Search

Hot Keywords

Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Kyung Bo Kim

Review|Published on: 30 May 2021
Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

Alice Romagnoli, ... Daniele Di Marino

Review|Published on: 11 May 2021

Submit a Manuscript

Review Articles See more

The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas

Anudeep Yekula, ... Leonora Balaj

Published on: 19 Mar 2021
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

Natasha Rinne, ... Paula Cunnea

Published on: 14 Apr 2021
The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

Elisabetta Pietri, ... Ingrid Garajová

Published on: 14 Apr 2021
Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer

Wing-Kee Lee, Thévenod Frank

Published on: 19 Jun 2021

Drug resistance in targeted cancer therapies with RAF inhibitors

Ufuk Degirmenci, ... Jiancheng Hu

Published on: 17 Jun 2021
Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Kyung Bo Kim

Published on: 30 May 2021
P53-regulated autophagy and its impact on drug resistance and cell fate

Daeun Shim, ... Carl G. Maki

Published on: 19 Mar 2021
Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

Anna Ulldemolins, ... Simo Schwartz Jr

video

Published on: 19 Mar 2021

Original Articles See more

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

I.V. Bijnsdorp, Godefridus J. Peters

Published on: 24 May 2021

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Xin Yu, ... Chunxia Su

Published on: 24 May 2021
Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging

Chelvam Venkatesh, ... Philip S. Low

Published on: 19 Mar 2021
Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Federica Bessone, ... Roberta Cavalli

Published on: 19 Mar 2021
A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Issa Ismail Issa, ... Karen Dybkær

video

Published on: 19 Mar 2021

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Jean-Marie Michot, ... Vincent Ribrag

Published on: 26 Mar 2021

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Derek A. Franklin, ... Justin M. Balko

Published on: 25 Apr 2020
Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel

Eiman Mukhtar, ... Paraskevi Giannakakou

Published on: 17 Apr 2020

Other Types of Articles See more

UCP2 - Taking the heat out of P-glycoprotein?

Richard Callaghan, Mary Board

Opinion|Published on: 19 Jun 2021

Advances in preclinical evaluation of experimental antibody-drug conjugates

Scott K. Lyons, ... Lloyd C. Trotman

Opinion|Published on: 4 Jul 2021
Tackling cisplatin resistance in ovarian cancer: what can we do?

Paola Perego

Editorial|Published on: 8 Jul 2021
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer

Jacopo Giuliani, Andrea Bonetti

Commentary|Published on: 27 Apr 2021
Overcoming drug resistance in glioblastoma: new options in sight?

Joanna Kopecka, Chiara Riganti

Editorial|Published on: 19 Jun 2021

Most Cited Papers In Last Two Years See more

Drug resistance and combating drug resistance in cancer

Xuan Wang, ... Xiaozhuo Chen

Review|Published on: 19 Jun 2019

MicroRNAs in neuroblastoma tumorigenesis, therapy resistance, and disease evolution

Natarajan Aravindan, ... Sheeja Aravindan

Review|Published on: 19 Dec 2019
Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors

Ratnakar Singh, ... Michael J. Spinella

Review|Published on: 19 Sep 2019

The role of exosomal long non-coding RNAs in cancer drug resistance

Mireia Cruz De los Santos, ... George A. Calin

Review|Published on: 19 Dec 2019

Ongoing Special Issues See more

Special Issue Ebooks See more

About The Journal

ISSN

2578-532X (Online)

Publisher

OAE Publishing Inc.

Article Processing Charges

$1200
Editor-in-Chief

Godefridus J. Peters

Publishing Model

Gold Open Access

Copyright

Copyright is retained by author(s)
Publication Frequency

Quarterly

Indexing

CAS

Journal Data Analysis

Total publications: 223

Total article views: 657,565

Total article downloads: 95,614

Open Archives

Portico

All published articles will be preserved here permanently:
https://www.portico.org/

Partners